Q1 2025 Management View Co-CEO Bob Duggan highlighted significant progress with ivonescimab, Summit Therapeutics' lead investigational asset, emphasizing its potential impact on unmet medical needs.

Nyrada Inc (ASX:NYR) is set to progress to the third cohort in its Phase 1 clinical trial assessing the safety, tolerability ...

A phase 1 trial has initiated and is investigating treatment with ziftomenib plus Gleevec in advanced GIST following ...

Avacopan has been shown to work well in a real-world setting in a much broader group of people with vasculitis than was studied in the phase 3 trial that led to its approval.

According to CEO Daniel Vitt, clinical and disability-related outcomes are more relevant than brain volume change for drug ...

Experts emphasize the need for enhanced clinical trial infrastructure in community oncology to ensure equitable access to ...

Cereno Scientific reported a successful meeting with the FDA on the design of a future clinical trial for its PAH therapy ...

Tresidder said his Melbourne-based firm has “a real focus” on biotech and life sciences. He sketched some of the ways brokers ...

Neoadjuvant PD-1 blockade in early-stage mismatch repair–deficient solid rectal and non-rectal tumors can eliminate the need ...

Tharimmune, Inc., (NASDAQ:THAR) (”Tharimmune” or the “Company”) a clinical-stage biopharmaceutical company focused on developing innovative therapeutics in inflammation & immunology, today announced ...

Discover phases of acute ischemic stroke care, from rapid recognition to long-term recovery strategies that neurologists use ...

Thermo Fisher Scientific is employing an enhanced platform technology and a new CHO K-1 cell line that can reduce timelines ...